Company Analysis
Sign in

Omeros Corporation (OMER)

Nasdaq: OMER · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 2004
Full chart Alerts Compare
Grade4.6
◀ Past 6.2● Present 5.6▶ Future 2.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

98 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Omeros Corporation’s names, not what it holds today.

Patents granted
98
98 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 11 in 2024 and 5 in 2023
Applications published
239
12 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals20
Organic fine chemistry7
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Omeros Corporation its own name
US, as the owner printed on each patent
98 granted
97 published
Omeros Corporation its own name
named as the applicant on its applications, in US
0 granted
142 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,278MASP-2 inhibitors and methods of useOrganic fine chemistryOmeros Corporation
Jul 8, 202512,351,648Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndromePharmaceuticalsOmeros Corporation
Jan 14, 202512,195,427MASP-2 inhibitors and methods of useOrganic fine chemistryOmeros Corporation
Oct 29, 202412,129,290Monoclonal antibodies, compositions and methods for detecting complement factor DBiotechnologyOmeros Corporation
Oct 8, 202412,110,288MASP-2 inhibitors and methods of useOrganic fine chemistryOmeros Corporation
Sep 17, 202412,091,468Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereofPharmaceuticalsOmeros Corporation
Jul 9, 202412,030,853MASP-2 inhibitors and methods of useOrganic fine chemistryOmeros Corporation
Jun 11, 202412,005,117Methods for inhibiting fibrosis in a subject in need thereofPharmaceuticalsOmeros Corporation
May 14, 202411,981,749Methods for treating conditions associated with MASP-2 dependent complement activationPharmaceuticalsOmeros Corporation
May 14, 202411,981,748Methods for inhibiting angiogenesis in a subject in need thereofPharmaceuticalsOmeros Corporation
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376443MASP-2 INHIBITORS AND METHODS OF USEOrganic fine chemistryOmeros Corporation
Dec 4, 20252025/0368604MASP-2 INHIBITORS AND METHODS OF USEOrganic fine chemistryOmeros Corporation
Jul 31, 20252025/0243198MASP-2 INHIBITORS AND METHODS OF USEOrganic fine chemistryOmeros Corporation
Jun 19, 20252025/0197349MASP-2 INHIBITORS AND METHODS OF USEOrganic fine chemistryOmeros Corporation
Jun 5, 20252025/0179160MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHODS FOR DETECTING COMPLEMENT FACTOR DBiotechnologyOmeros Corporation
Apr 24, 20252025/0129020MASP-2 INHIBITORS AND METHODS OF USEOrganic fine chemistryOmeros Corporation
Apr 17, 20252025/0122309Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the SamePharmaceuticalsOmeros Corporation
Apr 17, 20252025/0122225MASP-2 INHIBITORS AND METHODS OF USEPharmaceuticalsOmeros Corporation
Mar 20, 20252025/0092157METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOFPharmaceuticalsOmeros Corporation
Feb 27, 20252025/0066383PDE 7 MODULATOR COMPOUNDSPharmaceuticalsOmeros Corporation
What it applied for, 2024 to 2025: Pharmaceuticals 22 · Organic fine chemistry 10 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OMER · research, not advice